ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Promotion
Recombinantタンパク質s ClearClear history
Recombinantタンパク質s CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > IL-2 R beta

IL-2 R beta

概要

Name:Interleukin-2 receptor beta chain
Target Synonym:IL2RB,IMD63,IL-2RB,p75,CD122,Interleukin 2 Receptor Subunit Beta,Interleukin-15 Receptor Subunit Beta,Interleukin 15 Receptor, Beta,Interleukin 2 Receptor, Beta,IL-2R Subunit Beta,CD122 Antigen,P70-75,IL15RB,High Affinity IL-2 Receptor Beta Subunit,Interleukin-2 Receptor beta Subunit,Interleukin-2 receptor subunit beta,IL-2 receptor subunit beta,High affinity IL-2 receptor subunit beta
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase 3 Clinical

製品リスト製品比較と製品注文

製品> フィルター結果
製品仕様別：
製品カテゴリー別：
種類別：
タグ別：
コンジュゲート：
製造番号 種類 製品説明 構造 純度 特徴
ILB-C52H9 Cynomolgus Cynomolgus IL-2 R beta / CD122 Protein, His Tag (MALS verified)
ILB-C52H9-structure
ILB-C52H9-sds
ILB-M5253 Mouse Mouse IL-2 R beta / CD122 Protein, Fc Tag
ILB-M5253-structure
ILB-M5253-sds
ILA-C52H5 Canine Canine IL-2 R beta Protein, His Tag
ILA-C52H5-structure
ILA-C52H5-sds
ILA-M52H5 Mouse Mouse IL-2 R beta Protein, His Tag
ILA-M52H5-structure
ILA-M52H5-sds
ILB-H82E3 Human Biotinylated Human IL-2 R beta / CD122 Protein, His,Avitag™
ILB-H82E3-structure
ILB-H82E3-sds
ILB-H5253 Human Human IL-2 R beta / CD122 Protein, Fc Tag (MALS & SPR verified)
ILB-H5253-structure
ILB-H5253-sds
CD2-H5221 Human Human IL-2 R beta / CD122 Protein, His Tag (SPR verified)
CD2-H5221-structure
CD2-H5221-sds
ACRO Quality

生物活性データの一部

CD2-H5221-Cell-based assay
IL-2 R beta CELL

Human IL-2 R beta Protein, His Tag (Cat. No. CD2-H5221) inhibits the IL-15-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.38-0.45 µg/mL (Routinely tested).

Protocol
ILB-C52H9-SPR
IL-2 R beta SPR

Cynomolgus IL-2 R beta, His Tag (Cat. No. ILB-C52H9) immobilized on CM5 Chip can bind Cynomolgus IL-2, His Tag (Cat. No. IL2-C5249) with an affinity constant of 377 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
ILB-M5253-SPR
IL-2 R beta SPR

Mouse IL-2, His Tag (Cat. No. IL2-M52H3) immobilized on CM5 Chip can bind Mouse IL-2 R beta, Fc Tag (Cat. No. ILB-M5253) with an affinity constant of 36.2 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

Synonym Name

IL2RB,RP5-1170K4.6,CD122,P70-75

Background

Interleukin-2 receptor (IL-2R) is a heterotrimeric protein expressed on the surface of certain immune cells, such as lymphocytes, that binds and responds to a cytokine called IL-2. The IL-2R is made up of 3 subunits - α (CD25), β (CD122) and γ (CD132) - non-covalently associating. The α and β chains are involved in binding IL-2, while signal transduction following cytokine interaction is carried out by the γ-chain, along with the β subunit. CD122 is also known as IL2R beta, is a member of the type I cytokine receptor family. CD122 is the receptor for interleukin-2 and is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.

Clinical and Translational Updates

相関分子

IL-2 IL-15

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Bempegaldesleukin BMS-986321; ONO-7911; NKTR-214 Phase 3 Clinical Nektar Therapeutics Coronavirus Disease 2019 (COVID-19); Melanoma; Glioma; Lymphoma; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Ependymoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia; Medulloblastoma; Solid tumours Details
Nanrilkefusp alfa SO-C101; RLI-15; CYP-0150; SOT-101 Phase 2 Clinical Microsatellite instability-high cancer; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Prostatic Neoplasms, Castration-Resistant; Thyroid Diseases; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
GI-101 SIM-323; SIM323; GI-101 Phase 2 Clinical GI Innovation Inc Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
THOR-707 THOR-707; SAR-444245 Phase 2 Clinical Synthorx Inc Oropharyngeal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Esophageal adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Intestinal Neoplasms; Mesothelioma; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms Details
IPH-6501 IPH-6501; IPH-65 Phase 2 Clinical Innate Pharma SA Neoplasms; Lymphoma, Non-Hodgkin Details
IAP-0971 IAP-0971 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Solid tumours; Neoplasms; Urinary Bladder Neoplasms Details
TransCon IL-2 β/γ Phase 2 Clinical Ascendis Pharma A/S Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Neoplasm Metastasis Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma Details
Simlukafusp alfa FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP Phase 1 Clinical F. Hoffmann-La Roche Ltd Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma Details
BJ-001(Boji Biomedical Technology) BJ-001 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Communicable Diseases; Neoplasm Metastasis Details
STK-009 STK-009 Phase 1 Clinical Synthekine Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
FB-102 FB-102; FB102 Phase 1 Clinical Forte Biosciences Inc Alopecia Areata; Graft vs Host Disease; Vitiligo; Malabsorption Syndromes Details
NL-201 (Neoleukin Therapeutics) NL-201 Phase 1 Clinical Neoleukin Therapeutics Inc Solid tumours Details
Recombinant human interleukin 15(Beijing Kawin) Phase 1 Clinical Beijing Kawin Technology Share-Holding Co Ltd Solid tumours Details
Bempegaldesleukin BMS-986321; ONO-7911; NKTR-214 Phase 3 Clinical Nektar Therapeutics Coronavirus Disease 2019 (COVID-19); Melanoma; Glioma; Lymphoma; Sarcoma, Ewing; Brain Neoplasms; Neuroblastoma; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Ependymoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma; Head and Neck Neoplasms; Leukemia; Medulloblastoma; Solid tumours Details
Nanrilkefusp alfa SO-C101; RLI-15; CYP-0150; SOT-101 Phase 2 Clinical Microsatellite instability-high cancer; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Squamous Cell; Colorectal Neoplasms; Thymus Neoplasms; Urinary Bladder Neoplasms; Mesothelioma; Prostatic Neoplasms, Castration-Resistant; Thyroid Diseases; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Anus Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms Details
GI-101 SIM-323; SIM323; GI-101 Phase 2 Clinical GI Innovation Inc Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis Details
THOR-707 THOR-707; SAR-444245 Phase 2 Clinical Synthorx Inc Oropharyngeal Neoplasms; Melanoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Esophageal adenocarcinoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Intestinal Neoplasms; Mesothelioma; Skin Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms Details
IPH-6501 IPH-6501; IPH-65 Phase 2 Clinical Innate Pharma SA Neoplasms; Lymphoma, Non-Hodgkin Details
IAP-0971 IAP-0971 Phase 2 Clinical SunHo (China) BioPharmaceutical Co Ltd Solid tumours; Neoplasms; Urinary Bladder Neoplasms Details
TransCon IL-2 β/γ Phase 2 Clinical Ascendis Pharma A/S Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Neoplasm Metastasis Details
MDNA-11 MDNA-11; MDNA11 Phase 2 Clinical Medicenna Therapeutics Corp Triple Negative Breast Neoplasms; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Squamous Cell; Peritoneal Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Skin Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Stomach Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Gastrointestinal Diseases; Carcinoma, Basal Cell; Ovarian Neoplasms; Skin Melanoma Details
Simlukafusp alfa FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP Phase 1 Clinical F. Hoffmann-La Roche Ltd Head and Neck Neoplasms; Solid tumours; Carcinoma, Renal Cell; Esophageal Neoplasms; Breast Neoplasms; Uterine Cervical Neoplasms; Melanoma Details
BJ-001(Boji Biomedical Technology) BJ-001 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours; Communicable Diseases; Neoplasm Metastasis Details
STK-009 STK-009 Phase 1 Clinical Synthekine Inc Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lupus Nephritis; Lupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
FB-102 FB-102; FB102 Phase 1 Clinical Forte Biosciences Inc Alopecia Areata; Graft vs Host Disease; Vitiligo; Malabsorption Syndromes Details
NL-201 (Neoleukin Therapeutics) NL-201 Phase 1 Clinical Neoleukin Therapeutics Inc Solid tumours Details
Recombinant human interleukin 15(Beijing Kawin) Phase 1 Clinical Beijing Kawin Technology Share-Holding Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒157-0066
東京都世田谷区成城1丁目26番9-101号

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap